

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1 st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u>	National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u>
Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	Kind Attn.: Famroze Pochara Asst. Vice President
Code: 532321	Symbol: CADILAHC
Date: May 27, 2017	
Re.: Press Release	

Dear Sir / Madam,

We are forwarding herewith a copy of the Press Release proposed to be published in the newspapers in the matter of audited financial results for the quarter / year ended on March 31, 2017.

We request your good office to receive the same in order.

Thanking you,

Yours faithfully,
FOR CADILA HEALTHCARE LIMITED


UPEN H. SHAH
COMPANY SECRETARY



Encl.: As above

Zydus Cadila registers Net Profit of Rs. 1488 crores in FY 17

Ahmedabad, May 27, 2017

Announcing the results for the year ended 31st March 2017, Cadila Healthcare Limited informed that it has registered a Net Profit of Rs. 1488 crores on a consolidated basis. Consolidated total income from operations of the company during the year stood at Rs.9625 crores.

The company's formulations business in the US clocked sales of over US\$ 550 million during the year. The company's formulations business in India grew by 9% during the year on the back of launch of more than 75 new products, including line extensions.

Strengthening its regulatory pipeline, the company filed over 45 ANDAs during the year with the US FDA, taking the cumulative filings to over 305. The company received over 10 ANDA approvals during the year taking the total to over 110 product approvals.

For the fourth quarter ended 31st March 2017, the company registered total income from operations of Rs. 2525 crores, up by 6% from Rs. 2387 crores registered in the corresponding period last year on a consolidated basis. Net Profit for the same period stood at Rs. 386 crores.

During the fourth quarter ended 31st March 2017, the company made a foray into the specialty pain market in the US with the acquisition of Sentyln Therapeutics Inc., a US based specialty pharma company specialized in marketing of products in the pain management segment. The company completed the USFDA inspection at its Moraiya formulations facility with zero 483 observations during the fourth quarter. Apart from Moraiya, the company's oral solids manufacturing facilities in Ahmedabad SEZ and Baddi and topical manufacturing facility in Ahmedabad also completed USFDA inspections. Recently, the company successfully defended the claim of non-infringement in the US Court of Appeals for the Federal Circuit in case of Lialda® (Mesalamine 1.2 g DR tablets).
